Basic Information
| RNALocate ID: | RLID-D:11000530 |
| RNA Symbol: | hsa-miR-625-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-625-5p |
| RNA ID: | miRBase:MIMAT0003294 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| Tissue/Cell Line: | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
| Database: | EVmiRNA |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:11003313 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11003314 | Exosome | Plasma | 23663360 |
| RLID:11003315 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
| RLID:11003316 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11001388 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-625-5p | Oral squamous cell carcinoma | MNDR-E-MI-63846 |
| MNDR | hsa-miR-625-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-63847 |
| MNDR | hsa-miR-625-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-63848 |
| MNDR | hsa-miR-625-5p | Lymphoma | MNDR-E-MI-63849 |
| MNDR | hsa-miR-625-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-63850 |
| MNDR | hsa-miR-625-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-63851 |
| MNDR | hsa-miR-625-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-63852 |
| MNDR | hsa-miR-625-5p | Breast cancer luminal | MNDR-E-MI-63853 |
| MNDR | hsa-miR-625-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-63854 |
| MNDR | hsa-miR-625-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-63855 |
| MNDR | hsa-miR-625-5p | Small intestine cancer | MNDR-E-MI-63856 |
| MNDR | hsa-miR-625-5p | Prostate cancer | MNDR-E-MI-63857 |
| MNDR | hsa-miR-625-5p | Gastric cancer | MNDR-E-MI-63858 |
| MNDR | hsa-miR-625-5p | Alzheimer disease | MNDR-E-MI-63859 |
| MNDR | hsa-miR-625-5p | Dysautonomia familial | MNDR-E-MI-63860 |
| MNDR | hsa-miR-625-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-63861 |
| MNDR | hsa-miR-625-5p | Head and neck cancer | MNDR-E-MI-63862 |
| MNDR | hsa-miR-625-5p | Leukemia | MNDR-E-MI-63863 |
| MNDR | hsa-miR-625-5p | Cardiovascular disease | MNDR-E-MI-63864 |
| MNDR | hsa-miR-625-5p | Lung cancer | MNDR-E-MI-63865 |
| MNDR | hsa-miR-625-5p | Parkinson disease | MNDR-E-MI-63866 |
| MNDR | hsa-miR-625-5p | Machado-joseph disease | MNDR-E-MI-63867 |
| MNDR | hsa-miR-625-5p | Breast cancer | MNDR-E-MI-63868 |
| MNDR | hsa-miR-625-5p | Thyroid cancer | MNDR-E-MI-63869 |
| MNDR | hsa-miR-625-5p | Pituitary neoplasms | MNDR-E-MI-63870 |
| MNDR | hsa-miR-625-5p | Pancreatic cancer | MNDR-E-MI-63871 |
| MNDR | hsa-miR-625-5p | Melanoma | MNDR-E-MI-63872 |
| MNDR | hsa-miR-625-5p | Colon cancer | MNDR-E-MI-63873 |
| MNDR | hsa-miR-625-5p | Colon adenocarcinoma | MNDR-E-MI-63874 |
| MNDR | hsa-miR-625-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-63875 |
| MNDR | hsa-miR-625-5p | Familial ovarian cancer | MNDR-E-MI-63876 |
| MNDR | hsa-miR-625-5p | Acromegaly | MNDR-E-MI-63877 |
| MNDR | hsa-miR-625-5p | Asthma | MNDR-E-MI-63878 |
| MNDR | hsa-miR-625-5p | Carcinoma ductal breast | MNDR-E-MI-63879 |
| MNDR | hsa-miR-625-5p | Glioblastoma | MNDR-E-MI-63880 |
| MNDR | hsa-miR-625-5p | Glioma | MNDR-E-MI-63881 |
| MNDR | hsa-miR-625-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-63882 |
| MNDR | hsa-miR-625-5p | Epilepsy temporal lobe | MNDR-E-MI-63883 |
| MNDR | hsa-miR-625-5p | Liposarcoma | MNDR-E-MI-63884 |
| MNDR | hsa-miR-625-5p | Pituitary adenoma | MNDR-E-MI-63885 |
| MNDR | hsa-miR-625-5p | Lung squamous cell carcinoma | MNDR-E-MI-63886 |
| MNDR | hsa-miR-625-5p | Lung adenocarcinoma | MNDR-E-MI-63887 |
| MNDR | hsa-miR-625-5p | Thyroid carcinoma | MNDR-E-MI-63888 |
| MNDR | hsa-miR-625-5p | Ovarian carcinoma | MNDR-E-MI-63889 |
| MNDR | hsa-miR-625-5p | Carcinoma renal cell | MNDR-E-MI-63890 |
| MNDR | hsa-miR-625-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-63891 |
| MNDR | hsa-miR-625-5p | Renal clear cell carcinoma | MNDR-E-MI-63892 |
| MNDR | hsa-miR-625-5p | Cholangiocarcinoma | MNDR-E-MI-63893 |
| MNDR | hsa-miR-625-5p | Esophageal cancer | MNDR-E-MI-63894 |
| MNDR | hsa-miR-625-5p | Lung small cell carcinoma | MNDR-E-MI-63895 |
| MNDR | hsa-miR-625-5p | Testicular germ cell cancer | MNDR-E-MI-63896 |
| MNDR | hsa-miR-625-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-63897 |
| MNDR | hsa-miR-625-5p | Adenoma | MNDR-E-MI-63898 |
| MNDR | hsa-miR-625-5p | Breast invasive carcinoma | MNDR-E-MI-63899 |
| MNDR | hsa-miR-625-5p | Familiar ovarian carcinoma | MNDR-E-MI-63900 |
| MNDR | hsa-miR-625-5p | Esophagus small cell carcinoma | MNDR-E-MI-63901 |
| MNDR | hsa-miR-625-5p | Rheumatoid arthritis | MNDR-E-MI-63902 |
| MNDR | hsa-miR-625-5p | Hodgkin lymphoma | MNDR-E-MI-63903 |
| MNDR | hsa-miR-625-5p | Neuromyelitis optica | MNDR-E-MI-63904 |
| MNDR | hsa-miR-625-5p | Skin cutaneous melanoma | MNDR-E-MI-63905 |
| MNDR | hsa-miR-625-5p | Skin melanoma | MNDR-E-MI-63906 |
| MNDR | hsa-miR-625-5p | Colorectal cancer | MNDR-E-MI-63907 |
| MNDR | hsa-miR-625-5p | Nasopharynx carcinoma | MNDR-E-MI-63908 |
| MNDR | hsa-miR-625-5p | Multiple myeloma | MNDR-E-MI-63909 |
| MNDR | hsa-miR-625-5p | Nasopharyngeal cancer | MNDR-E-MI-63910 |
| MNDR | hsa-miR-625-5p | Stroke lacunar | MNDR-E-MI-63911 |
| MNDR | hsa-miR-625-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-63912 |
| MNDR | hsa-miR-625-5p | Tubulovillous adenoma | MNDR-E-MI-63913 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | FHIT | Homo sapiens | RR00565469 |
TOP